Fertility management and outcomes after CAR T-cell therapy: an international survey from the Cellular Therapy and Immunobiology working party of the European Society for Blood and Marrow Transplantation.

Fiche publication

Date publication

juin 2026

Journal

EClinicalMedicine

Auteurs

Membres identifiés du Cancéropôle Est :
Dr PAGLIUCA Simona

Tous les auteurs :
Orofino G, Sánchez-Ortega I, Mota JS, Aroldi A, Castilla-Llorente C, Bigenwald C, Dalle JH, Yacouben K, Di Blasi R, Galli E, Grandage V, Palasciano A, Bacon L, Franke GN, Fandrei D, Merz M, George L, Lopez-Corral L, Hecker JS, Mannina D, Bramanti S, Martin Gonzalez JA, Martínez-Cibrian N, Petersen SL, Polgarova K, Protheroe R, Richardson D, Ram R, Elias S, von Tresckow B, Stölzel F, Streiss I, Vallet N, Knippenberg J, Tomas AA, Pagliuca S, Malard F, Kuball J, Ruggeri A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42317792

Résumé

CAR T-cell therapy has become a highly effective treatment for hematological malignancies, and emerging evidence indicates promising benefits for non-oncohematological conditions. As its clinical use broadens, understanding long-term outcomes and late complications is crucial. One critical yet understudied area is fertility, for which current evidence remains limited and no formal guidelines provide direction for patients undergoing CAR T-cell therapy.